Epidermal growth factor receptor gene mutation and computed tomographic findings in peripheral pulmonary adenocarcinoma

Journal of Thoracic Oncology

Volumn 1, Issue 5, 2006, Pages 413-416

  Yano, Motoki ^a,b   Sasaki, Hidefumi ^a   Kobayashi, Yoshihiro ^a   Yukiue, Haruhiro ^a   Haneda, Hiroshi ^a   Suzuki, Eriko ^a   Endo, Katsuhiko ^a   Kawano, Osamu ^a   Hara, Masaki ^a   Fujii, Yoshitaka ^a  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^b Department of Surgery II ^*  (Japan)

Author keywords

Lung cancer; Lung cancer surgery; Radiology

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER PATIENT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATIONAL STUDY; DELETION MUTANT; EXON; FEMALE; GENE DELETION; GENE MUTATION; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; SMOKING; STATISTICAL SIGNIFICANCE; TUMOR VOLUME; WILD TYPE; ADENOCARCINOMA; GENETICS; LUNG TUMOR; MIDDLE AGED; MUTATION; RADIOGRAPHY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34247197735     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01243894-200606000-00006     Document Type: Article

References (18)

1. Yada I, Wada H, Shinoda M, Yasuda K. Committee of Science, Japanese Association for Thoracic Surgery. Thoracic and cardiovascular surgery in Japan during 2001: annual report by the Japanese Association for Thoracic Surgery. Jpn J Thorac Cardiovasc Surg 2003;51:699-716.
2. Naruke T, Tsuchiya R, Kondo H, Asamura H. Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNMstaging classification: the Japanese experience. Ann Thorac Surg 2001;71:1759-1764.
3. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909.
4. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-2246.
5. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-2158.
6. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
7. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
8. Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64:8919-8923.
9. Janne PA, Gurubhagavatula S, Yeap BY, et al. Outcomes of patient with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study. Lung Cancer 2004;44:221-230.
10. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small- cell lung cancer. J Clin Oncol 2004;22:1103-1109.
11. Endo K, Konishi A, Sasaki H, et al. Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. Lung Cancer 2006;50:375-384.
12. Huang SF, Liu HP, Li LH, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004;10:8195-8203.
13. Chou TY, Chiu CH, Li LH, et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 2006;11:3750-3757.
14. Travis WD, Garg K, Franklin WA, et al. Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. J Clin Oncol 2006;23:3279-3287.
15. Aoki T, Tomoda Y, Watanabe H, et al. Peripheral lung adenocarcinoma: correlation of thin-section CT findings with histologic prognostic factors and survival. Radiology 2001;220:803-809.
16. Haneda H, Sasaki H, Lindeman N, et al. A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma. Jpn J Clin Oncol 2006;36:69-75.
17. Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2006;23:2513-2520.
18. Moriguchi H, Kim TY, Sato C. Gefitinib for refractory advanced non-small-cell lung cancer. Lancet 2006;367:299-300.